JP2022532402A5 - - Google Patents

Info

Publication number
JP2022532402A5
JP2022532402A5 JP2021568309A JP2021568309A JP2022532402A5 JP 2022532402 A5 JP2022532402 A5 JP 2022532402A5 JP 2021568309 A JP2021568309 A JP 2021568309A JP 2021568309 A JP2021568309 A JP 2021568309A JP 2022532402 A5 JP2022532402 A5 JP 2022532402A5
Authority
JP
Japan
Prior art keywords
cells
molecule
target
optionally
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021568309A
Other languages
English (en)
Japanese (ja)
Other versions
JP7682104B2 (ja
JP2022532402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032968 external-priority patent/WO2020232292A1/en
Publication of JP2022532402A publication Critical patent/JP2022532402A/ja
Publication of JP2022532402A5 publication Critical patent/JP2022532402A5/ja
Priority to JP2025030838A priority Critical patent/JP2025084874A/ja
Application granted granted Critical
Publication of JP7682104B2 publication Critical patent/JP7682104B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021568309A 2019-05-15 2020-05-14 非小細胞肺がんを処置するための方法および組成物 Active JP7682104B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025030838A JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848123P 2019-05-15 2019-05-15
US62/848,123 2019-05-15
PCT/US2020/032968 WO2020232292A1 (en) 2019-05-15 2020-05-14 Methods and compositions for treating non-small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025030838A Division JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2022532402A JP2022532402A (ja) 2022-07-14
JP2022532402A5 true JP2022532402A5 (enExample) 2023-05-22
JP7682104B2 JP7682104B2 (ja) 2025-05-23

Family

ID=73289322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568309A Active JP7682104B2 (ja) 2019-05-15 2020-05-14 非小細胞肺がんを処置するための方法および組成物
JP2025030838A Withdrawn JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025030838A Withdrawn JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Country Status (6)

Country Link
US (1) US20220265847A1 (enExample)
EP (1) EP3969121A4 (enExample)
JP (2) JP7682104B2 (enExample)
KR (1) KR20220009446A (enExample)
CN (1) CN114126719A (enExample)
WO (1) WO2020232292A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114075548B (zh) * 2020-08-13 2023-11-21 广州医科大学附属第二医院 一种靶向axl的car-t细胞及其制备方法和应用
CN117897405A (zh) * 2021-06-30 2024-04-16 得克萨斯大学体系董事会 靶向cd70-阳性癌症的多肽
WO2023102119A1 (en) * 2021-12-01 2023-06-08 The Brigham And Women's Hospital, Inc. Multispecific t cell engager polypeptides in combination with t cells for cancer therapy
WO2023100153A1 (en) * 2021-12-03 2023-06-08 Crispr Therapeutics Ag Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy
WO2025180385A1 (en) * 2024-02-27 2025-09-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/cd70 antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015200386A1 (en) * 2008-04-11 2015-02-19 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
WO2012135841A2 (en) * 2011-04-01 2012-10-04 Board Of Regents, The University Of Texas System Emt signatures and predictive markers and method of using the same
CN111499684B (zh) * 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
EP3541389A1 (en) * 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
EP3583129B1 (en) * 2017-02-14 2021-11-03 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
US20200063100A1 (en) * 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer

Similar Documents

Publication Publication Date Title
Li et al. Recent advances in therapeutic strategies for triple-negative breast cancer
JP6999577B2 (ja) がんを処置するための抗ｐｄ－１抗体と放射線の組合せ
JP7564122B2 (ja) 光免疫療法のための方法および関連バイオマーカー
Vacchelli et al. Trial watch: Monoclonal antibodies in cancer therapy
Saletta et al. Advances in paediatric cancer treatment
JP2022078265A (ja) 肺癌の処置のための抗ｐｄ－１抗体
Moek et al. The antibody–drug conjugate target landscape across a broad range of tumour types
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
JP2024545427A (ja) Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組み合わせ療法
JP7740994B2 (ja) 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療
TW201731527A (zh) 使用抗ｐｄ－１抗體與抗ｃｌｔａ－４抗體之組合以治療肺癌
JP2024545428A (ja) 癌治療における患者選択のためのｃｅａアッセイ
JP2024545428A5 (enExample)
WO2023201267A1 (en) Combination therapy for treating trop-2 expressing cancers
Avanzino et al. A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer
Zhang et al. Preclinical study of a novel tri-specific anti-CD3/CD19/CD20 T cell-engaging antibody as a potentially better treatment for NHL
Espinosa-Cotton et al. Immunotherapy and radioimmunotherapy for desmoplastic small round cell tumor
Bertucci et al. PELICAN-IPC 2015-016/Oncodistinct-003: a prospective, multicenter, open-label, randomized, non-comparative, phase II study of pembrolizumab in combination with neo adjuvant EC-paclitaxel regimen in HER2-negative inflammatory breast cancer
Carter et al. Immuno-oncology agents for cancer therapy
Shim et al. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
Qi et al. The co-inhibitory immune checkpoint proteins B7-H1 (PD-L1) and B7-H4 in high grade glioma: from bench to bedside
WO2025169012A1 (en) Methods of treating ceacam5-expressing cancers
Li et al. A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer
WO2019155000A1 (en) Treatment of car t-cell toxicity
JP2024516230A (ja) がんのための治療及び診断方法並びに組成物